The Relationship between Platelet Aggregation and Time Interval after Venepuncture

1974 ◽  
Vol 31 (01) ◽  
pp. 133-141 ◽  
Author(s):  
Charles Warlow ◽  
Anne Corina ◽  
D Ogston ◽  
A. S Douglas

SummaryThe relationship between the rate of platelet aggregation and the time interval after venepuncture has been studied. Considerable changes in the rates of aggregation and disaggregation of platelets in citrated plasma take place between 30 and 120 minutes after venepuncture. There is a reduction in the rates of irreversible ADP-induced aggregation, the first and second phase of the double wave of ADP-induced aggregation, disaggregation after reversible ADP-induced aggregation, collagen-induced aggregation and the second phase of the double wave of adrenaline-induced aggregation. In contrast, the rate of the first wave of adrenaline-induced aggregation increases with time after venepuncture. 5-HT induced aggregation appears to be unaffected. These effects were not due to changes in the pH of the plasma. It is suggested that any attempt to quantify platelet aggregation during the comparison of groups of individuals, or in the study of the effect of anti-platelet drugs in single individuals must take into account the time interval between venepuncture and the measurement of platelet aggregation.

1981 ◽  
Author(s):  
David C Stump ◽  
Donald E Macfarlane

Epinephrine induces platelet aggregation, potentiates aggregation by other agents, and blocks the stimulation of the adenylate cyclase by prostaglandins. Synthetic α-adrenergic agents have not been shown to induce aggregation. The effects of clonidine, an α2-agonist, and ρ-aminoclonidine on platelets were examined. Clonidine potentiated aggregation induced by 0.5μM ADP by 1.4-fold (1/2 max 0.5μM). It did not induce significant aggregation itself, and it inhibited aggregation induced by 5μM epinephrine (1/2 max lμM). It inhibited cyclic AMP accumulation induced by PGE1 by a maximum of 25% (1/2 max O.lμM) and it blocked inhibition by epinephrine. No significant specific binding of [3H] clonidine was observed to intact platelets. ρ-Aminoclonidine induced aggregation with delayed second phase (1/2 max 0.2μM), and potentiated ADP aggregation by 2-fold (1/2 max 0.2μM). Aggregation induced by epinephrine was more rapid, and was partially inhibited by ρ-aminoclonidine. It inhibited cyclic AMP accumulation by 50% max (1/2 max O.lμM) and attenuated epinephrine’s effect to the same level. The direct effects of ρ-aminoclonidine were blocked by lμM yohimbine, a selective α2-antagonist. Both clonidine and ρ—aminoclonidine blocked the specific binding of [3H]yohimbine (1/2 max 0.5μM). These results suggest that the platelet bears an α2-receptor with affinity for epinephrine, ρ-aminoclonidine and clonidine as agonists but that these agents display differing intrinsic activity and/or receptor reserve.


1977 ◽  
Vol 28 (1) ◽  
pp. 211-223
Author(s):  
D.E. MacIntyre ◽  
A.P. Allen ◽  
K.J. Thorne ◽  
A.M. Glauert ◽  
J.L. Gordon

Endotoxin lipopolysaccharide (LPS) from Acinetobacter 199A induced aggregation of blood platelets from immune adherence-positive species (rat, rabbit) but not from immune adherence-negative species such as pig and man. Aggregation occurred in 2 phases: the first was not accompanied by secretion of platelet constituents, was apparently a consequence of C3 activation, and was selectively inhibited by EGTA. The second phase of aggregation was associated with secretion of platelet granule contents, and with a lesser amount of cytoplasmic leakage. Secondary aggregation was abolished by the sulphydryl alkylating agent N-ethylmaleimide, and by agents which increased the level of cyclic AMP in platelets, such as prostaglandin E1 (a stimulator of adenylate cyclase) and methyl xanthines (inhibitors of phosphodiesterase). Secondary aggregation was partly inhibited by agents which block platelet prostaglandin biosynthesis (e.g. aspirin, indomethacin). Primary aggregation was unaffected by these inhibitors at concentrations which blocked secondary aggregation.


1977 ◽  
Author(s):  
K. Breddin ◽  
H.J. Krzywanek

ADP-, collagen and epinephrine-induced aggregation change markedly if citrate blood or PRP are kept at different incubation temperatures or/and if the time interval between blood sampling and testing varies. With a growing time interval the response of PRP to ADP, collagen or epinephrine increases. Desaggregation after ADP-aggregation decreases with time. If PRP is incubated at 4°C or 10°C aggregation is increased in comparison with room temperature. At 37°C aggregation is markedly inhibited. This inhibitory effect is almost fully reversible several hours after blood sampling. Corresponding results were obtained with PAT III, measuring spontaneous aggregation tendency. Morphologic platelet changes show some correlation with the time and temperature dependent changes of the aggregation pattern. In clinical studies the time interval between blood sampling and testing and the incubation temperature of PRP should be strictly controlled. If enhanced platelet aggregation is to be studied the time interval between venepuncture and performance of the test should be 30 - 60 min for ADP-or collagen-induced aggregation and between 90 and 360 min for PAT III. PRP should always be kept at 20 - 25°C.


Blood ◽  
1975 ◽  
Vol 45 (3) ◽  
pp. 403-412 ◽  
Author(s):  
HJ Weiss

Ristocetin was used to study platelet aggregation in platelet-rich plasma and to assay the von Willebrand factor activity of factor VIII (VIII-VWF). Ristocetin-induced platelet aggregation (RIPA) was decreased in 13 of 18 patients with von Willebrand's disease (VWD) who had decreased plasma levels of VIII-VWF. The five patients with normal RIPA appeared to have mild VWD but did not constitute a separate subclass. RIPA was also abnormal in some patients with intrinsic platelet defects, but in no case was the defect corrected by normal plasma. The latter type of correction appears to be specific for VWD. Aspirin ingestion inhibited the second phase of RIPA (at low concentrations of ristocetin only) but did not affect the initial phase of aggregation or the level of VIII-VWF. We also studied a group of patients who had both abnormalities of the factor VIII complex and intrinsic platelet defects, such as impaired collagen-induced aggregation, as well. The findings in these patients and in those with typical von Willebrand's disease appear to comprise a spectrum of disorders (the von Willebrand syndrome) in which some abnormality of the factor VIII complex is associated with impaired platelet function. At present, ristocetin would appear to be a useful reagent for evaluating patients with bleeding disorders and for studying patients with the von Willebrand syndrome.


1984 ◽  
Vol 62 (3) ◽  
pp. 338-340
Author(s):  
J. J. F. Killackey ◽  
B. A. Killackey ◽  
I. Cerskus ◽  
R. B. Philp

A hydroperoxide compound structurally related to acetylsalicylic acid, 3-hydroperoxy-3-methylphthalide, inhibits both the first and second phases of adenosine diphosphate induced, biphasic, human platelet aggregation. This occurs over the same concentration range (0.05–0.5 mM) that acetylsalicylic acid inhibits second phase aggregation and the release reaction only. The complete inhibition of adenosine diphosphate induced aggregation is a unique pharmacological property for an acetylsalicylic-acid-like compound.


1972 ◽  
Vol 28 (02) ◽  
pp. 221-227 ◽  
Author(s):  
James W. Davis ◽  
Kenneth T. N. Yue ◽  
Phyllis E. Phillips

SummaryIncubation of human platelet-rich plasma (PRP) with neuraminidase enhanced platelet aggregation induced by adenosine diphosphate (ADP), norepinephrine, collagen or serotonin. Both first and second phases of ADP- and norepinephrine -induced aggregation were enhanced. In two plasmas a second phase of ADP-induced aggregation occurred after incubation with neuraminidase, but not in the control preparations. In one plasma a second phase of serotonin-induced platelet aggregation occurred after incubation with neuraminidase. The incubation of PRP with exogenous N-acetylneuraminic acid (a product of the action of neuraminidase) had no effect on platelet aggregation. A possible explanation of the observed enhancement of platelet aggregation by neuraminidase is that the enzyme may have released sialic acid from platelet membranes and thereby reduced their net negative surface charge.


2006 ◽  
Vol 95 (03) ◽  
pp. 476-482 ◽  
Author(s):  
Eric Lim ◽  
Martin Goddard ◽  
Sarah Bellm ◽  
Kate Sheridan ◽  
Stephen Large ◽  
...  

SummaryThe failure of aspirin to inhibit platelet function has been documented in patients undergoing coronary artery bypass graft (CABG) surgery, but the causes of “aspirin-resistance” remain uncertain. The aim of this study was to investigate the efficacy of aspirin in patients undergoing CABG surgery receiving either 100 mg or 325 mg of oral aspirin for 5-days.Platelet function was tested the day before surgery and on day+1 and day+5, and evaluated by changes in collagen-induced thromboxane-A2 (TxA2) release and platelet aggregation following stimulation with collagen, ADP and epinephrine. In all patients, baseline platelet aggregation was significantly inhibited by pre-incubation with in vitro aspirin (150 µmol/l), with a mean reduction in TxA2-release of ≥95.5% (82.3, 99.1). After 5-days of oral aspirin, platelet aggregation was significantly inhibited, and was not further inhibited by in vitro aspirin. Oral aspirin was also associated with a ≥99.5% (97.8, 99.7) reduction in TxA2-release, and with the reversal of the second-phase of ADP-induced aggregation which is TxA2-dependent. In addition a single-dose of 325mg aspirin on the first post-operative morning may have a greater inhibitory effect on collagen-induced aggregation than 100mg aspirin. Western blot analysis provided no evidence for the presence of COX-2 in platelets, while the up-regulation of p38-MAPK following platelet-stimulation and surgery was seen. The inhibition of COX-2 (NS398) or p38-MAPK (SB203580) activity did not affect platelet aggregation and TxA2-release on day+5. In summary, there was no evidence for inherent or acquired aspirin-resistance in this surgical population, or for the involvement of either COX-2 or p38-MAPK.


1977 ◽  
Author(s):  
S. Heptinstall ◽  
G.P. Mulley

Preparations of heparinized platelet rich plasma (PRP) from 54 different volunteers were examined to determine the extent of platelet aggregation and release reaction both in the absence and presence of citrate. Platelet aggregation was studied in fresh untreated samples of PRP using a range of concentrations of ADP. To study release reaction platelets in a portion of each preparation were labelled with 3H-5-hydroxytryptamine. Released radioactivity was measured after stirring with ADP or with ADP and citrate.Even in the absence of citrate release was considerable in 26 of the preparations. There was a good correlation between extent of aggregation and extent of release reaction. When second phase aggregation occurred release was extensive, when release was low or absent the higher concentrations of ADP were required to bring about “irreversible” aggregation. Whenever citrate was present release reaction was enhanced. Enhanced release reaction was also observed in PRP in which the bulk of plasma calcium had been exchanged for sodium by ion exchange chromatography.It is concluded that ADP induced release reaction can occur in heparinized PRP but that it is enhanced by reducing the concentration of extracellular ionised calcium.


Blood ◽  
1971 ◽  
Vol 38 (4) ◽  
pp. 417-421 ◽  
Author(s):  
JAMES W. DAVIS ◽  
PHYLLIS E. PHILLIPS

Abstract Since imidazole buffers have been used in platelet function tests and the compound has been reported to alter several biochemical activities of platelets, it seemed important to determine whether imidazole influenced platelet aggregation. ADP-induced, collagen-induced, and norepinephrine-induced platelet aggregations were tested in platelet-rich plasma by turbidimetric techniques. Glass bead-induced platelet aggregation in whole blood was tested by a method dependent upon platelet counts. Imidazole, in concentrations of 5mM or less, inhibited aggregation induced by each of these four agents and had negligible effect on the pH of platelet-rich plasma. The second phase of both ADP- and norepinephrine-induced aggregation was inhibited or abolished by imidazole, and 5mM imidazole also inhibited the first phase of norepinephrine-induced aggregation. As little as 0.5 mM imidazole inhibited collagen-induced aggregation in some plasmas. Imidazole appears to be unsuitable for use as a buffer in platelet function tests.


1975 ◽  
Author(s):  
O. Tangen ◽  
S. Bygdeman

The effect of some selected inhibitors of platelet release reaction and blood clotting on collagen- and adrenaline-induced human platelet aggregation was investigated by means of the turbidimetric method according to Born. Acetylsalicylic acid (ASA) inhibited both collagen- and adrenaline-induced platelet aggregation in citrated platelet rich plasma (PRP). Addition of sufficient amounts of Ca++ to give concentrations similar to those in native blood suppressed the inhibition by small doses of ASA (5–10 μg/ml) on collagen-induced aggregation and the second phase of adrenaline-induced aggregation. Higher concentrations of ASA (13–30 μg/ml) could partly overcome this effect of Ca++. Heparin, which had no effect on primary adenosine diphosphate (ADP)-induced aggregation, inhibited platelet aggregation induced by collagen. In contrast, both the first and second phase of adrenaline-induced aggregation was markedly potentiated by heparin. Dextran sulphate had effects basically similar to heparin, Nicotinic acid inhibited collagen-induced aggregation, but had no effect on the second phase of adrenaline-induced aggregation. These results indicate that the platelet release reaction induced by collagen and adrenaline is mediated via separate receptors or reaction pathways.


Sign in / Sign up

Export Citation Format

Share Document